Jijun Wang is a distinguished Principal Scientist at Pfizer, where he leverages over 13 years of extensive experience in the pharmaceutical industry to drive innovative drug discovery initiatives, particularly in the realms of neuroscience, inflammation, and fibrosis. As the in vivo pharmacology lead, Jijun plays...
Jijun Wang is a distinguished Principal Scientist at Pfizer, where he leverages over 13 years of extensive experience in the pharmaceutical industry to drive innovative drug discovery initiatives, particularly in the realms of neuroscience, inflammation, and fibrosis. As the in vivo pharmacology lead, Jijun plays a pivotal role in shaping the strategic direction of Pfizer’s portfolio by designing and implementing robust in vivo strategies that are critical for the success of both early and late-stage programs. His expertise in animal disease models, including non-alcoholic steatohepatitis (NASH) and lung/skin fibrosis, positions him as a key contributor to advancing therapeutic candidates through pre-clinical and clinical phases.
Jijun excels in fostering effective collaborations within a cross-functional matrixed environment, establishing productive relationships with internal teams, academic partners, and Contract Research Organizations (CROs). His ability to communicate complex timelines and data delivery expectations ensures that project milestones are met efficiently, thereby enhancing the overall productivity of the research teams. With a diverse skill set that encompasses immunology, RNA interference (RNAi), and epigenetics, Jijun is adept at integrating cutting-edge methodologies such as Luminex assays and chromatin immunoprecipitation into his research. His leadership in project management not only drives scientific innovation but also cultivates a culture of excellence and collaboration within Pfizer, ultimately contributing to the development of transformative therapies that address unmet medical needs.
